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Abstract. Special aT-rich sequence binding protein 1 (SaTB1) 
regulates the expression of more than 1,000 genes in tumor 
cells. SaTB1 expression has been implicated in metastasis, 
and its silencing results in reduced cancer progression and the 
reversion of metastatic cells to normal appearance. Therefore, 
any compound causing down-regulation of SaTB1 expres-
sion or activity may be exploited for its therapeutic potential 
in terms of cancer regression. earlier studies showed that 
the 3-hydroxy-3-methylglutaryl coenzymea (HMG-coa) 
reductase inhibitors (statin drugs), which are widely used to 
treat hypercholesterolemia, possess other pleotropic activities. 
These are now increasingly gaining attention for their cancer 
prevention abilities. However, the downstream interplay of the 
molecular mechanisms of such anti-cancer activities is unclear. 
Here, we show that SaTB1 is down-regulated by statins in a 
time- and dose-dependent manner in colo205 cells. This 
effect was statin-specific as the down-regulation of SATB1 
was brought about by hydrophobic statins, such as simvastatin 
and fluvastatin, but not by hydrophilic pravastatin. Notably, 
treatment with mevalonate, an intermediate in the cholesterol 
and isoprenoid biosynthetic pathways, led to the inhibition of 
SaTB1 down-regulation and cytotoxicity mediated by statins. 
Treatment with the proteasome inhibitors lactacystine and 
MG-132 inhibited the statin-mediated down-regulation of 
SaTB1, suggesting that regulation occurs at the post-transla-
tional level. Thus, our results demonstrate a novel molecular 
mechanism for the anti-cancer activity of statin drugs in colon 
cancer cells, without invoking significant cytotoxicity. 
Introduction
The 3-hydroxy-3-methylglutaryl coenzymea (HMG-coa) 
reductase inhibitors (statin drugs) are widely used to treat 
hypercholesterolemia by reducing serum cholesterol levels (1). 
They act as competitive inhibitors of HMG-coa reductase, a 
rate limiting enzyme in the cholesterol and isoprenoid biosyn-
thetic pathways. emerging research suggests that statins may 
also have tumoricidal effects and are implicated in tumor 
regression, although the results have been mixed (2,3). Statins 
have been shown to regress in vitro and in vivo tumor growth 
and to inhibit metastasis at clinically relevant doses (4,5). 
nevertheless, the intricate molecular mechanism(s) of statin-
induced cancer cell death are not completely understood. 
Special aT-rich sequence binding protein (SaTB1) is 
a matrix attachment region (Mar)-binding protein that 
participates in higher-order chromatin organization and tissue-
specific gene expression. SATB1 has recently been shown 
to be the ‘master regulator’ of global gene expression (6,7). 
Furthermore, phosphorylation of SaTB1 acts as a molecular 
switch in determining whether it acts as a transcriptional 
activator or repressor (7). at the genome-wide level, SaTB1 
organizes and regulates transcriptionally poised genes (8). 
intriguingly, SaTB1 is up-regulated during malignancy, 
markedly altering the gene expression profile of cancer cells 
to induce an aggressive phenotype that promotes both tumor 
growth and metastasis (6). Strikingly, knockdown of SaTB1 
in aggressive breast cancer cells reverses metastasis (6). 
The objective of this study was to examine whether the 
genome organizer SaTB1 is regulated through the cholesterol or 
isoprenoid biosynthetic pathways. We observed that the inhibi-
tion of mevalonate, a common precursor of both the cholesterol 
and isoprenoid biosynthetic pathways by HMG-coa reductase 
inhibitors (statins), or the addition of geranylgeranyl transferase 
inhibitor (GGTI-298), which specifically and significantly 
blocks the geranylgeranylation of rho/rac GTPases, dimin-
ished SaTB1 levels in colon cancer colo205 cells, thereby 
implicating the isoprenoid-mediated regulation of SaTB1. This 
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down-regulation of SaTB1 protein may in part be responsible 
for the anti-cancer activities of statin drugs.
Materials and methods
Reagents. Fluvastatin, simvastatin, geranylgeranyl transferase 
inhibitor (GGTi)-298 and farnesyl transferase inhibitor 
(FTi)-277 were from calbiochem. 3-(4,5-dimethylthiazol-
2-yl)-2,5 diphenyl tetrazolium bromide (MTT), mevalonate, 
clasto-lactacystine β-lactone and MG-132 were from Sigma, inc. 
cell culture media were purchased from life Technologies.
Cell culture. colo205, k562 cells were grown in rPMi-1640; 
HepG2, Sk-n-SH cells in dMeM; McF-7, MdaMB-231 cells 
in MeM. Medium was supplemented with 10% FBS, containing 
penicillin (100 u/ml), streptomycin (100 µg/ml) and glutamine 
(4 mM). all cell lines were originally obtained from aTcc.
Cytotoxicity/cell proliferation assay. The effect of statins on 
the viability of colo205 cells was monitored by the MTT 
assay. At ~70% confluence, cells were treated with simvas-
tatin, fluvastatin or pravastatin at different concentrations 
(0-75 µM) as a function of time in the presence or absence of 
different concentrations of mevalonate (0-75 µM). after the 
treatments, MTT was added to a final concentration of 1 mg/
ml and further incubated for 1 h at 37˚C in a humidified 5% 
co2 incubator. cells were dissolved in 1 ml of dMSo and 
readings were taken at 570 nm in a Spectrophotometer.
Preparation of whole cell extracts. after treatment, cells 
were homogenized in 200 µl riPa buffer containing protease 
inhibitor cocktail. The lysate was centrifuged at 750 x g for 
10 min at 4˚C to pellet out the nuclei. The remaining super-
natant was centrifuged for 30 min at 13,000 x g. Protein was 
determined using the lowry method and 40 µg of the lysate 
was used for Western blot analysis using anti-rabbit SaTB1, 
as previously described (7). 
RT-PCR. Total rna was isolated using Trizol reagent, 
and cdna was prepared using Superscript ii reverse tran-
scriptase (invitrogen). Primer sequences used for SaTB1 
were: forward 5'-GTGGaaGccTTGGGaaTcc-3'; reverse 
5'-cTGacaGcTcTTcTTcTaGTT-3'. 
Results
Statin-mediated down-regulation of SATB1. SaTB1 is known 
to be expressed in multiple cell types, but at varying levels (9). 
Therefore, we screened for the basal levels of SaTB1 protein 
in different carcinoma cell lines. of the eight different cell 
lines tested, SaTB1 protein levels were found to be highest in 
colo205 (colon carcinoma) followed by k562 (erythromy-
eloblastoid leukaemia), and relatively low levels were observed 
in Sk-n-SH (neuroblastoma) and McF7 cells (Fig. 1a). 
Since the endogenous expression of SaTB1 was found to be 
highest in colo205 cells, we performed subsequent experi-
ments using these cells. To study the effect of HMG-coa 
reductase inhibitors on SaTB1 levels, colo205 cells were 
treated with simvastatin, fluvastatin and pravastatin (25 µM) 
for 48 h. Simvastatin and fluvastatin are hydrophobic, whereas 
pravastatin is hydrophilic. it was observed that simvastatin 
and fluvastatin significantly depleted SATB1 protein levels 
(Fig. 1B), whereas pravastatin had no effect (Fig. 1B), thereby 
suggesting that only hydrophobic statins are more effective in 
down-regulating SaTB1 levels. To determine whether statin-
mediated effects on SaTB1 protein were due to HMG-coa 
reductase inhibition, cells were pre-treated with mevalonate 
(50 µM) prior to the addition of statins. it was found that 
mevalonate completely reversed simvastatin and fluvastatin 
induced the down-regulation of SaTB1 (Fig. 1B). next, we 
studied the dose- and time-dependent effects of statins on 
SaTB1. For this, cells were treated with two different doses 
(25 and 50 µM) of simvastatin for various time periods 
(0-48 h). SaTB1 levels appeared to decrease by 24 h with 
50 µM, and by 36 h with 25 µM of simvastatin (Fig. 1c), and 
the addition of mevalonate alleviated the down-regulation of 
SaTB1 by simvastatin (Fig. 1c). 
Statin-induced cytotoxicity in COLO205: Effect of 
mevalonate supplementation. We examined the effective-
ness of simvastatin, fluvastatin and pravastatin in causing 
cytotoxicity to colo205 cells employing the MTT assay. 
The viability of simvastatin and fluvastatin (25 µM)-treated 
cells was reduced to ~75% compared to untreated conditions 
by 48 h, whereas in the presence of mevalonate (50 µM), cell 
viability was completely restored. By contrast, pravastatin 
had no effect on cell viability (Fig. 2a). next, the cytotoxicity 
assay was performed in cells treated with various concentra-
tions of simvastatin (0-75 µM) in the presence or absence 
of mevalonate (50 µM) for different time periods (0-48 h). 
Simvastatin dose- and time-dependently decreased cell 
viability by ~50% in colo205 cells, with maximum effect 
at 50 and 75 µM (Fig. 2B). Similarly, the addition of various 
concentrations of mevalonate (50-100 µM) along with simvas-
tatin (50 µM) either completely (at 50 and 75 µM mevalonate) 
or partially (at 25 µM mevalonate) protected cells from statin-
induced cytotoxicity (Fig. 2c).
Down-regulation of SATB1 by simvastatin is at the post-
translational level: Effect of proteasomal inhibitors. Having 
observed that simvastatin down-regulates SaTB1 protein in 
colo205 cells, we examined whether the regulation of SaTB1 
by statins occurs at the transcription level. To our surprise, 
SATB1 transcript levels did not change significantly with 
statins (Fig. 3a). owing to this discrepancy, we then proceeded 
to test whether the proteasomal pathway plays any role in the 
proteolytic degradation of SaTB1 protein in colo205 cells 
by statins. To this end, cells were incubated with proteasomal 
inhibitors, lactacystine (10 µM) and MG-132 (5 µM) 2 h prior to 
the addition of simvastatin (25 µM) for 48 h. it was found that 
both the proteasomal inhibitors significantly restored the SATB1 
levels as compared to statin alone-treated cells (Fig. 3B), thus 
implicating the proteasomal enzyme system in the regulation 
of SaTB1 under these experimental conditions. However, the 
proteasomal inhibitors did not affect statin-induced cytotoxicity 
(Fig. 3c). additionally, we investigated the role of isoprenyla-
tion in the statin-mediated down-regulation of SaTB1 levels. 
it was observed that the incubation of colo205 cells with 
GGTI-298 (20 µM), but not with FTI-277 (20 µM), significantly 
reduced SaTB1 levels when incubated for 48 h (Fig. 3d). This 
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Figure 1. effect of statins and mevalonate on SaTB1 levels in colo205 cells. (a) endogenous expression levels of SaTB1 protein in various cancerous cell 
lines. Protein (40 µg) from each cell extract was loaded for Western blot analysis. (B) Effect of simvastatin, fluvastatin and pravastatin (at 25 µM) on SATB1 
protein levels, with or without mevalonate (50 µM) supplementation in colo205 cells treated for 48 h. Protein (40 µg) from each treatment was used for 
Western blot analysis. (c) Western blot showing the time- and dose-dependent down-regulation of SaTB1 by simvastatin and its reversion with mavelonate 
supplementation. Panels represent treatments durations of 24, 36 and 48 h, respectively. immunoblot analysis using anti-β-actin served as the loading control.
Figure 2. Effect of mevalonate on statin-induced cytotoxicity in COLO205 cells. (A) Cells were treated with either simvastatin, fluvastatin or pravastatin 
(25 µM) in the presence or absence of mevalonate (50 µM) for 48 h, and cell viability was measured by the MTT assay. (B) cells were treated with varying 
concentrations of simvastatin (25-75 µM) for different time periods (12-48 h) in the presence or absence of mevalonate (50 µM), and cell death was measured 
by the MTT assay. (c) as above, except that simvastatin (50 µM)-induced cell death was measured in the presence of varying concentrations of mevalonate 
(50-100 µM). Values are the mean ± Se of three independent experiments. *Significantly different compared to untreated conditions.
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result emphasizes the involvement of the geranylgeranylation of 
certain rho or rac GTPases in regulating SaTB1 protein.
Discussion 
although recent research has shown that SaTB1 promotes 
increased metastasis-associated gene transcriptions on the 
one hand, and inhibits tumor suppressor genes on the other 
(6), combined with the earlier reports on the role of SaTB1 
in the development of thymocytes (10,11), it remains unclear 
how SaTB1 itself is regulated to re-program global gene 
expression profiles. In this study, we showed that HMG-CoA 
reductase inhibitors (statins) down-regulate SaTB1, thereby 
implicating either cholesterol intermediates or isoprenoids 
in the regulation of SaTB1 levels in colon carcinoma cells. 
Moreover, only hydrophobic statins (simvastatin and fluvas-
tatin) and not hydrophilic statins, like pravastatin, were found 
to be effective in causing altered regulation of SaTB1 and 
increased cytotoxicity. This result is in agreement with recent 
reports on the differential activity of statins in breast and other 
gynecological cancers (5,12).
Statins dysregulate the cholesterol and isoprenoid biosyn-
thetic pathways (13). The end-products of these pathways are 
required for a number of essential cellular functions, including 
cell motility, proliferation, apoptosis and membrane integrity. 
Furthermore, they are involved in carcinogenesis (14). Many 
cancer cell types express elevated levels of HMG-coa 
reductase activity to satisfy their needs for increased prolifera-
tion, thus making it an attractive chemotherapeutic target (15). 
Statins have been shown to induce apoptosis, and inhibit cell 
proliferation in various tumor-derived cells, including colon 
cancer (16). in a recent population-based case-control study, 
the use of statins was associated with a 50% reduction in the 
risk of colorectal cancer incidence (17). 
One of the interesting findings of our study is that, although 
SaTB1 protein is altered by statins, the regulation is not at the 
transcriptional level. Simvastatin and fluvastatin significantly 
down-regulated SaTB1 protein levels both in a dose- and time-
dependent manner. We therefore investigated the involvement 
of the proteasome-mediated degradation of SaTB1 protein by 
these statins. Proteasomal inhibitors significantly restored the 
SaTB1 protein levels to near untreated conditions, implicating 
that statins may induce post-translational modification(s) of 
SaTB1, which in turn targets it for proteolytic degradation 
through the proteasomal enzyme machinery. nevertheless, a 
thorough understanding of this mechanism must be reached in 
the near future, along with the regulation of SaTB1 by statins 
in other cancer cell types. 
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Figure 3. effect of proteasomal inhibitors and the role of isoprenylation on statin-induced down-regulation of SaTB1 in colo205 cells. (a) SaTB1 transcript 
levels in cells treated with simvastatin at the indicated concentrations was performed by rT-Pcr, as described in Materials and methods. GaPdH transcripts 
served as loading control. (B) cells were treated with simvastatin (25 µM) for 48 h in the presence or absence of either mevalonate (50 µM) or proteasomal 
inhibitors (MG-132, 5 µM; lactacystin, 10 µM). Proteasomal inhibitors were added 2 h prior to the addition of simvastatin. Bar graph depicts normalized band 
intensity values of SaTB1 protein levels of the Western blot panels shown below. (c) cell viability was estimated using the MTT assay at 48 h. data are the 
mean ± Se of three independent experiments. (d) cells were treated with either GGTi-298 (20 µM) or FTi-277 (20 µM) for 48 h, and immunoblotting was 
performed as described in Materials and methods. *Significantly different from simvastatin alone-treated conditions.
Molecular Medicine rePorTS  3:  857-861,  2010 861
The data presented here additionally suggest that the 
cholesterol-independent pathways are responsible for statin-
mediated STaB1 down-regulation. HMG-coa reductase 
inhibitors deplete the availability of prenylated substrates (18). 
The post-translational prenylation of GTPases, by the addition 
of geranylgeranyl or farnesyl moiety, is critical for cellular 
localization and signalling activities (19). in this study, we 
found that treatment with geranylgeranyl transferase inhibitor 
(GGTi-298), but not farnesyl transferase inhibitor (FTi-277), 
resulted in the down-regulation of SaTB1, thus mimicking 
the statin-mediated effects. Therefore, it is likely that statin-
mediated down-regulation of SaTB1 occurs through reduced 
geranylgeranylation of downstream signaling targets, such as 
rho or rac GTPases.
In conclusion, this is the first report demonstrating that 
SaTB1, the global chromatin organizer and gene regulator, is 
itself regulated by HMG-coa reductase inhibitors (statins). 
This is presumably mediated via the inhibition of the isopre-
nylation of small GTPases in colon carcinoma cells. However, 
the detailed mechanism of how this is brought about remains 
to be further investigated. 
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